Professional Experience:

1. Chief Expert, Liver Transplantation Center, Jilin University: Leads academic and surgical advancements with a wealth of experience in general surgery, especially in hepatobiliary and pancreatic surgery.

· Achieved Jilin Province's first independent liver transplant in 2013.

· Successfully led over 700 liver transplants by 2022, spanning a range of complexities.

2. Director, Jilin Organ Transplantation Quality Control Center: Upholds and oversees the highest standards in organ transplantation.

3. Esteemed Vice Chairman, Organ Transplantation Branch, Jilin Medical Association: Contributes to the growth and progress of transplant medicine in the Jilin region.

Academic Contributions:

· Publications: Authored over 100 academic articles, including 68 SCI papers. Regular contributor to esteemed journals like Hepatology and Journal of Hepatology.

· Books: Contributed to six authoritative monographs in the field.

· Patents: Holds ten patented inventions.

· Research Leadership: Spearheaded projects backed by the National Natural Science Foundation of China, with involvement in 20 additional projects. Accumulated funding exceeds 20 million yuan.

Editorial Roles:

· Co-Editor-in-Chief, eGastroenterology: Oversees content and quality for a leading international gastroenterology journal.

· Editorial Board Member:

· Chinese Journal of Hepatobiliary Surgery

· Chinese Journal of Organ Transplantation

· Journal of Clinical Hepatology

Professional Affiliations:

· Distinguished Member, Standing Committee, Organ Transplantation Branch: Health Exchange and Cooperation Across the Taiwan Straits Association. Dedicated to the betterment of transplant medicine.

Publication

· 1. Chen L, Qiu W, Sun X, Gao M, Zhao Y, Li M, Fan Z*, Lv G*. Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis. Gut. 2024 Feb 23;73(3):521-532. (IF= 24.5)

· 2. Shi A, Liu Z, Fan Z, Li K, Liu X, Tang Y, Hu J, Li X, Shu L, Zhao L, Huang L, Zhang Z, Lv G*, Zhang Z*, Xu Y*. Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment. Gut. 2024 Mar 8:gutjnl-2023-331715. (IF= 24.5)

· 3. Fan Z, Jin M, Zhang L, Wang N, Li M, Wang C, Wei F, Zhang P, Du X, Sun X, Qiu W, Wang M, Wang H, Shi X, Ye J, Jiang C, Zhou J, Chai W, Qi J, Li T, Zhang R, Liu X, Huang B, Chai K, Cao Y, Mu W, Huang Y, Yang T, Zhang H, Qu L, Liu Y, Wang G, Lv G*. From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification. Gut. 2023 Nov;72(11):2149-2163. (IF= 24.5)

· 4. Chen L, Fan Z, Zhao Y, Yang H, Lv G*. Genetic factors in the clinical predictive model for hepatocellular carcinoma: Evidence from genetic association analyses. Journal of Hepatology. 2023 Jan 3:S0168-8278(22)03476-6. (IF= 25.7)

· 5. Chen L, Fan Z, Lv G*. Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants. Journal of Hepatology. 2022 Nov;77(5):1453-1454. (IF= 25.7)

· 6. Fan Z, Zou X, Wang G, Liu Y, Jiang Y, Wang H, Zhang P, Wei F, Du X, Wang M, Sun X, Ji B, Hu X, Chen L, Zhou P, Wang D, Bai J, Xiao X, Zuo L, Xia X, Yi X, Lv G*. A transcriptome based molecular classification scheme for cholangiocarcinoma and subtype-derived prognostic biomarker. Nat Commun. 2024 Jan 11;15(1):484. (IF= 16.6)

· 7. Dong T, Hu G*, Fan Z, Wang H, Gao Y, Wang S, Xu H, Yaffe MB, Vander Heiden MG, Lv G*, Chen J*. Activation of GPR3-β-arrestin2-PKM2 pathway in Kupffer cells stimulates glycolysis and inhibits obesity and liver pathogenesis. Nat Commun. 2024 Jan 27;15(1):807. (IF= 16.6)

· 8. Li T, Yang Y, Li Y, Wang Z, Ma F, Luo R, Xu X, Zhou G, Wang J, Niu J, Lv G*, Crispe IN*, Tu Z*. Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein. J Clin Invest. 2022 Feb 15;132(4):e150101. (IF= 15.9)

· 9. Chen L, Yang H, Li H, He C, Yang L, Lv G*. Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study. Hepatology. 2022 Apr;75(4):785-796. doi: 10.1002/hep.32183. (IF= 13.5)

· 10. Luo F, Li M, Chen Y, Song S, Yu H, Zhang P*, Xiao C*, Lv G*, Chen X. Immunosuppressive enzyme-responsive nanoparticles for enhanced accumulation in liver allograft to overcome acute rejection. Biomaterials. 2024 Apr;306:122476. (IF= 14.0)

· 11. Ma E, Ai J, Zhang Y, Zheng J, Gao X, Xu J, Yin H, Fu Z, Xing H, Li L, Sun L, Huang H, Zhang Q, Xu L, Jin Y, Chen R, Lv G*, Zhu Z*, Zhang W*, Wang Z*. Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort. Emerg Microbes Infect. 2022 Dec;11(1):2636-2644. (IF= 13.2)

· 12. Fan ZQ, Serenari M, Lv X, Schwartz M, Qiu W, Pawlik TM, Chen Z, Zhou YH, Wang XM, Chen TH, Li J, Zhang CW, Wang H, Zhang YM, Gu WM, Liang YJ, Diao YK, Yao LQ, Li C, Cescon M, Wang MD, Sun XD, Lau WY, Shen F, Yang T*, Lv G*. Prognostic significance of nodular number in patients undergoing hepatectomy of intermediate-stage hepatocellular carcinoma. Br J Surg. 2024 Mar 2;111(3):znae047. (IF= 9.6)

· 13. Li M, Song S, Tian G, Zhi Y, Chen Y, et.al, Lv G*. Expansion kinetics of graft-versus-host T cell clones in patients with post-liver transplant graft-versus-host disease. Am J Transplant. 2022 Nov;22(11):2689-2693. (IF= 8.8)

· 14. Chai K, Wang C, Zhou J, Mu W, Gao M, Fan Z*, Lv G*. Quenching thirst with poison? Paradoxical effect of anticancer drugs. Pharmacol Res. 2023 Dec;198:106987. (IF= 9.3)

· 15. Chen L, Fan Z, Sun X, Qiu W, Mu W, Chai K, Cao Y, Wang G, Lv G*. Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study. Hepatol Int. 2023 Apr;17(2):326-338. (IF= 6.6)

· 16. Yang A, Zhu X, Zhang L, Zhang Y, Zhang D, Jin M, Niu J, Zhang H, Ding Y*, Lv G*. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study. Hepatol Int. 2022 Oct;16(5):1035-1051. (IF= 6.6)

· 17. Xu X, Wang MD, Xu JH, Fan ZQ, Diao YK, Chen Z, Jia HD, Liu FB, Zeng YY, Wang XM, Wu H, Qiu W, Li C, Pawlik TM, Lau WY, Shen F, Lv GY*, Yang T*. Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis. Front Immunol. 2024 Jan 8;14:1322233. (IF= 6.6)

· 18. Song S, Zhi Y, Tian G, Sun X, Chen Y, Qiu W, Jiao W, Huang H, Yu Y, Li M*, Lv G*. Immature and activated phenotype of blood NK cells is associated with acute rejection in adult liver transplant. Liver Transpl. 2023 Aug 1;29(8):836-848. (IF= 4.6)

· 19. Chen L, Zhao Y, Li M, Lv G*. Proteome-wide Mendelian randomization highlights AIF1 and HLA-DQA2 as targets for primary sclerosing cholangitis. Hepatol Int. 2024 Apr;18(2):517-528. (IF= 6.6)

· 20. Pu JL, Xu X, Chen LL, Li C, Jia HD, Fan ZQ, Li JD, Guan MC, Liang YJ, Zhou YH, Wang XM, Gu WM, Wang H, Li J, Chen ZY, Chen TH, Zhang YM, Chen ZX, Yao LQ, Diao YK, Wang MD, Shen F, Pawlik TM, Lau WY, Chen Z*, Yang T*, Lv GY*. Postoperative infectious complications following laparoscopic versus open hepatectomy for hepatocellular carcinoma: a multicenter propensity score analysis of 3876 patients. Int J Surg. 2023 Aug 1;109(8):2267-2275. (IF= 15.3)

· 21. Zhang H, Chen L, Fan Z*, Lv G*. The causal effects of inflammatory bowel disease on primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study. Liver Int. 2023 Aug;43(8):1741-1748. (2区，IF= 6.7)

· 22. Fan Z, Liu Y, Li C, Jiang Y, Wang N, Wang M, Li C, Diao Y, Qiu W, Zhu X, Wang G, Cai S, Yang T*, Lv G*. T proliferating cells derived autophagy signature associated with prognosis and immunotherapy resistance in a pan-cancer analysis. iScience. 2023 Dec 8;27(1):108701. (IF= 5.8)

· 23. Li S, Zhi Y, Mu W, Li M, Lv G*. Exploring the effects of epigallocatechin gallate on lipid metabolism in the rat steatotic liver during normothermic machine perfusion: Insights from lipidomics and RNA sequencing. Eur J Pharmacol. 2024 Feb 5;964:176300. (IF= 5.0)

· 24. Yao LQ, Fan ZQ, Wang MD, Diao YK, Chen TH, Zeng YY, Chen Z, Wang XM, Zhou YH, Li J, Fan XP, Liang YJ, Li C, Shen F*, Lv GY*, Yang T*. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis. Ann Surg Oncol. 2024 Feb;31(2):1219-1231. (IF= 3.7)